These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 23257230)

  • 1. Reanalysis of TransVax immunogenicity.
    Kharfan-Dabaja MA; Boeckh M; Wilck MB; Langston AA; Chu AH; Wloch MK; Smith LR; Rolland AP; Kenney RT
    Lancet Infect Dis; 2013 Jan; 13(1):18. PubMed ID: 23257230
    [No Abstract]   [Full Text] [Related]  

  • 2. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Kharfan-Dabaja MA; Boeckh M; Wilck MB; Langston AA; Chu AH; Wloch MK; Guterwill DF; Smith LR; Rolland AP; Kenney RT
    Lancet Infect Dis; 2012 Apr; 12(4):290-9. PubMed ID: 22237175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Could a vaccine against immune-evading cytomegalovirus become a reality?
    Emery VC
    Expert Rev Vaccines; 2011 Aug; 10(8):1109-11. PubMed ID: 21854303
    [No Abstract]   [Full Text] [Related]  

  • 4. Vaccines against human cytomegalovirus: time to test.
    Britt WJ
    Trends Microbiol; 1996 Jan; 4(1):34-8. PubMed ID: 8824793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of cytomegalovirus disease by Towne strain live attenuated vaccine.
    Plotkin SA; Smiley ML; Friedman HM; Starr SE; Fleisher GR; Wlodaver C; Dafoe DC; Friedman AD; Grossman RA; Barker CF
    Birth Defects Orig Artic Ser; 1984; 20(1):271-87. PubMed ID: 6329367
    [No Abstract]   [Full Text] [Related]  

  • 6. Cell-mediated immunity to cytomegalovirus in mice and in renal transplant recipients.
    Howard RJ; Balfour HH
    Transplant Proc; 1979 Mar; 11(1):75-8. PubMed ID: 222021
    [No Abstract]   [Full Text] [Related]  

  • 7. Cytomegalovirus vaccine live (Pasteur Mérieux Connaught).
    Drugs R D; 1999 Nov; 2(5):310-2. PubMed ID: 10728468
    [No Abstract]   [Full Text] [Related]  

  • 8. Enhancement of humoral immune responses to a human cytomegalovirus DNA vaccine: adjuvant effects of aluminum phosphate and CpG oligodeoxynucleotides.
    Temperton NJ; Quenelle DC; Lawson KM; Zuckerman JN; Kern ER; Griffiths PD; Emery VC
    J Med Virol; 2003 May; 70(1):86-90. PubMed ID: 12629648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus vaccines: current status.
    Starr SE
    Infect Agents Dis; 1992 Jun; 1(3):146-8. PubMed ID: 1365538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [VP22 enhances the immunological activity of human cytomegalovirus pp65 DNA vaccine: experimental study with mice].
    Ma DX; Yu XP; Zhang XM; Zhou YB; Li Y; Jia JH; Zhao WM
    Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(15):1049-52. PubMed ID: 16029549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).
    Adler SP; Plotkin SA; Gonczol E; Cadoz M; Meric C; Wang JB; Dellamonica P; Best AM; Zahradnik J; Pincus S; Berencsi K; Cox WI; Gyulai Z
    J Infect Dis; 1999 Sep; 180(3):843-6. PubMed ID: 10438376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune response to CMV in solid organ transplant recipients: current concepts and future directions.
    Watkins RR; Lemonovich TL; Razonable RR
    Expert Rev Clin Immunol; 2012 May; 8(4):383-93. PubMed ID: 22607184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new look at a poorly immunogenic neutralization epitope on cytomegalovirus glycoprotein B. Is there cause for antigen redesign?
    Ohlin M
    Mol Immunol; 2014 Aug; 60(2):95-102. PubMed ID: 24802891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of morbidity and mortality of wild murine cytomegalovirus by vaccination with attenuated cytomegalovirus.
    Howard RJ; Balfour HH
    Proc Soc Exp Biol Med; 1977 Nov; 156(2):365-8. PubMed ID: 200952
    [No Abstract]   [Full Text] [Related]  

  • 15. Vaccination against cytomegalovirus, the changeling demon.
    Plotkin SA
    Pediatr Infect Dis J; 1999 Apr; 18(4):313-25; quiz 326. PubMed ID: 10223683
    [No Abstract]   [Full Text] [Related]  

  • 16. Cytomegalovirus vaccine in renal transplant candidates: progress report of a randomized, placebo-controlled, double-blind trial.
    Balfour HH; Sachs GW; Welo P; Gehrz RC; Simmons RL; Najarian JS
    Birth Defects Orig Artic Ser; 1984; 20(1):289-304. PubMed ID: 6329368
    [No Abstract]   [Full Text] [Related]  

  • 17. [Vaccines against cytomegalovirus infect. Perspectives].
    Cadoz M; Méric C
    Arch Pediatr; 1999; 6 Suppl 3():655s-658s. PubMed ID: 10429809
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of temperature-sensitive mutants of mouse cytomegalovirus as vaccines.
    Sandford GR; Burns WH
    J Infect Dis; 1988 Sep; 158(3):596-601. PubMed ID: 2842407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CMV vaccine shows impressive control in nonhuman primates.
    IAVI Rep; 2011; 15(3):19. PubMed ID: 21809803
    [No Abstract]   [Full Text] [Related]  

  • 20. Cytomegalovirus vaccine development--past and present.
    Plotkin SA
    Transplant Proc; 1991 Jun; 23(3 Suppl 3):85-9. PubMed ID: 1648842
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.